The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
A technical recession occurs when there are two consecutive quarters of economic contraction.Asia Economyread more
"Deepfakes" are being used to depict people in fake videos they did not actually appear in, and can potentially affect elections, diplomacy and how markets move, experts say.Technologyread more
A spokesperson for the U.S.-backed Syrian Democratic Forces (SDF) has issued a stark warning to the international community.World Newsread more
The potential deal would shift Neumann's already diminished voting power to the Japanese conglomerate, according to the Journal.Technologyread more
U.S. President Donald Trump said that both sides reached a "very substantial phase one deal" that will address intellectual property and financial services concerns and...Asia Marketsread more
On Friday, Zedd tweeted about the ban, and CNBC verified the claim with his publicist on Saturday.China Politicsread more
Hunter's vows to forgo any foreign work follow a slew of unsubstantiated attacks by President Donald Trump accusing him of corruption.Politicsread more
Apple, the company that created the modern-day smartphone, is relying on technology customers are already extremely familiar with, like cameras, and taking a backseat when it...Technologyread more
Fisher was initially defiant amid the backlash in an interview with Bloomberg, in which he said he had "given a lot of talks, a lot of times, in a lot of places and said stuff...Personal Financeread more
The bids come as Chinese companies face tightening scrutiny on their overseas investments. Chinese regulators are reviewing deal agreements in minute details, and have cracked down on some large domestic conglomerates, including Fosun, for their debt-fuelled acquisitions abroad.
Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> said in a stock exchange filing its Hong Kong unit submitted on July 19 a non-binding bid for a stake in Arbor, which is backed by private equity firm KKR & Co LP.
In a separate filing, Shanghai Pharma also said it had submitted a non-binding bid for a stake in Arbor on the same day.
Both companies did not disclose the quantum of stakes they had bid for nor the financial terms but said they have not entered exclusive talks with the seller.
Fosun Pharma said its Hong Kong unit will begin conducting due diligence to determine further steps.
Arbor has appointed Bank of America Merrill Lynch to run the sale process, which has attracted around half a dozen preliminary bids, mostly from Chinese companies and private equity firms, according to people familiar with matter.
The bank did not immediately respond to a Reuters request for comment.
Some of the bidders may seek to acquire control of the company, said two of the people, adding that discussions are at an early stage still.
A potential deal could value Arbor at around $3 billion, two of the people said.
Bloomberg, which first reported on the sale process, said the bidders were seeking to buy 20 percent to 30 percent of Arbor.
Arbor did not immediately respond to a Reuters query for comment. The sources could not be named as the discussions are confidential.
Atlanta-based Arbor produces mainly branded prescription drugs for the pediatric, hospital and cardiovascular markets.
New York-based KKR agreed to buy more than a quarter of shares in the company in December 2014, in a deal that valued privately held Arbor at over $1 billion, Reuters reported at the time.